Hansen, Mueller Industries director, sells $105,710 in stock
Investing.com - TD Cowen has reiterated its Buy rating on DexCom (NASDAQ:DXCM) with a price target of $100.00 ahead of the company’s third-quarter earnings report, scheduled for October 30. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $83 to $115.
The firm believes concerns about the reliability of DexCom’s G7 continuous glucose monitoring system have been "blown out of proportion," creating what it describes as an attractive risk-reward setup for investors. The company’s strong financial health score of "GREAT" on InvestingPro supports this outlook, with robust cash flows and moderate debt levels.
TD Cowen expects DexCom’s upcoming third-quarter results to address these reliability concerns and potentially drive a recovery in the stock price through the end of the year.
The research firm maintains a positive outlook beyond the immediate quarter, specifically highlighting the fourth-quarter results and 2026 guidance expected in February as the next significant milestone for the company.
The firm’s analyst Joshua Jennings reaffirmed the Buy rating on DexCom shares in his latest research note to investors.
In other recent news, DexCom has been the focus of several analyst reports and market developments. Piper Sandler maintained an Overweight rating with a $100 price target, expressing confidence in DexCom’s upcoming third-quarter earnings. Stifel resumed coverage with a Buy rating, highlighting the potential of DexCom’s 15-day sensor and growing market share in the Type 2 diabetes segment. TD Cowen also reiterated a Buy rating and a $100 price target, noting that earlier issues with the G7 continuous glucose monitoring system have mostly been resolved. UBS defended its Buy rating and set a $106 price target, despite concerns over increased MAUDE events related to the G7 sensor. Meanwhile, Hunterbrook Media issued a short report alleging serious safety issues with the G7 device, claiming that inaccurate readings have led to hospitalizations and deaths. The report also accused DexCom of making an unauthorized design change to a key component of the G7. These developments have sparked a range of reactions from analysts and investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.